-
A
Representative photographs of the ears of WT mice (left panel) and RIG‐I−/− mice (right panel) after administration of imiquimod (IMQ) for 7 days, n = 4 per group.
-
B
The ear thickness of WT and RIG‐I−/− mice on the indicated day presented relative to day 0. Significant differences are indicated: one‐way ANOVA, n = 4 per group (mean ± SEM).
-
C
Representative H&E staining of the ears treated as in (A), n = 4 per group. Scale bar: 200 μm.
-
D
Acanthosis of WT and RIG‐I−/− mice treated with imiquimod. Significant differences are indicated: two‐tailed Student's t‐test, n = 5 per group (mean ± SEM).
-
E
Representative immunostaining of Ki67 in ear skin derived from WT and RIG‐I−/− mice treated with imiquimod, n = 5 per group. Scale bar: 100 μm.
-
F
Quantitation of Ki67+ cells in ear skin derived from WT and RIG‐I−/− mice treated with imiquimod. Significant differences are indicated: two‐tailed Student's t‐test, n = 5 per group (mean ± SEM).
-
G, H
ELISA detection of IL‐23p19 (G) and IL‐17 (H) protein levels in supernatants of ear skin homogenates derived from indicated groups. Significant differences are indicated: two‐tailed Student's t‐test, n = 3–4 per group (mean ± SEM).